目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状...目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状病毒疫苗的新型冠状病毒感染诊断分型(轻型、中型、重型及危重型)的差别。阶段性总结新型冠状病毒感染住院患者的治疗情况及疗效分析;并促进各医院新型冠状病毒感染整体诊治水平的提高,指导康复及下一阶段可能出现高峰时的治疗。方法:回顾性收集并分析陕西省抗癫痫协会会员单位医院的其中10家医院的神经内科及神经外科在2022年12月13日~2023年1月31日期间收治的新型冠状病毒感染住院患者的临床资料,评价各型新型冠状病毒感染诊断分型中各治疗组疗效和接种疫苗对诊断分型的影响。结果:对363例患者临床资料进行统计学分析,在新型冠状病毒感染诊断分型为轻型的住院患者中,抗新型冠状病毒组与非抗新型冠状病毒组之间(P Objective: To compare the differences in the number of days of hospitalization and treatment outcomes in patients with the various diagnostic types of novel coronavirus infection with and without anti-novel coronavirus therapy, with and without hormone therapy, with and without antibiotic therapy, with and without traditional Chinese medicine, and vaccinated and unvaccinated against novel coronavirus;comparison of the diagnostic classification of novel coronavirus infections (mild, moderate, severe and critical) between those vaccinated and those not vaccinated against novel coronaviruses. We will summarize the treatment of hospitalized patients with novel coronavirus infections and analyze the therapeutic efficacy in a staged manner, and promote the improvement of the overall diagnosis and treatment of novel coronavirus infections in hospitals to guide the rehabilitation and the treatment of novel coronavirus infections in the next stage, when the peak may occur. Methods: Retrospective collection and analysis of clinical data of patients hospitalized with novel coronavirus infections admitted to the Department of Neurology and Department of Neurosurgery of 10 of the hospitals that are members of the Shaanxi Provincial Anti-Epilepsy Association during the period of December 13, 2022~January 31, 2023, to evaluate the efficacy of treatment groups in the diagnostic typing of novel coronavirus infections of each type and the effect of vaccination on the diagnostic typing. Results: The clinical data of 363 patients were statistically analyzed. Among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, there were statistically significant differences in hospital days between the anti-novel coronavirus group and the non-anti-novel coronavirus group (P < 0.001) and between the hormone group and the non-hormone group (P = 0.006). There was a statistically significant difference in hospital days between the antibiotic group and the non-antibiotic group among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, moderate and severe (P < 0.001, P = 0.005, P = 0.045), and between-group variability in treatment outcomes between the vaccine and non-vaccine groups among hospitalized patients whose diagnostic typology of novel coronavirus infection was medium (P = 0.024);the likelihood of a diagnosis of critical illness was higher in the non-vaccine than in the vaccine group, relative to the mild type (OR = 11.463, 95% CI 1.352~97.186, P = 0.025). Conclusions: The application of anti-novel coronavirus therapy, hormone therapy and antibiotic therapy may increase hospital days in hospitalized patients with a diagnostic classification of mild forms of novel coronavirus infection, and the application of antibiotic therapy in hospitalized patients with a diagnostic classification of moderate and severe forms of novel coronavirus infection;the vaccine group of hospitalized patients with a diagnostic classification of moderate forms of novel coronavirus infection was more likely to have a positive outcome of the treatment, relative to the control group. Vaccination may have a positive effect on preventing progression to critical type after COVID-19 infection.展开更多
目的:探讨心血管危险因素对非动脉炎性前部缺血性视神经病变(NAION)的发生及视功能的影响。方法:选取2014-06/2018-06于我科就诊的单眼初发NAION患者(NAION组)和与其基本资料匹配的非NAION患者(对照组)各68例68眼,检测两组患者同型半胱...目的:探讨心血管危险因素对非动脉炎性前部缺血性视神经病变(NAION)的发生及视功能的影响。方法:选取2014-06/2018-06于我科就诊的单眼初发NAION患者(NAION组)和与其基本资料匹配的非NAION患者(对照组)各68例68眼,检测两组患者同型半胱氨酸(Hcy)、血脂、叶酸、维生素B12水平,并进行颈动脉多普勒超声检查,NAION组患者同时进行视功能检查。结果:与对照组相比,NAION组患者Hcy(24.8±13.9μmol/L vs 11.1±8.2μmol/L)、血浆中总胆固醇(4.5±1.0mmol/L vs 3.8±0.7mmol/L)、甘油三酯(2.0±0.9mmol/L vs 1.5±0.5mmol/L)、低密度脂蛋白(2.9±0.8mmol/L vs 2.3±0.5mmol/L)水平均升高(P<0.05),维生素B12水平明显下降(315.6±214.5pg/mL vs 467.9±198.2pg/mL,P<0.05),但两组患者颈内动脉阻力指数和内径无差异。NAION组患者患眼视野缺损值为16.6±7.5dB,Hcy、维生素B12、叶酸及血脂水平以及是否存在全身疾病均不是NAION视野损害的危险因素,而图形视觉诱发电位P100波幅和潜伏期峰值均与视野缺损值相关。结论:高同型半胱氨酸、高血脂和低维生素B12水平是NAION发生的危险因素,但与NAION的视野损害程度无关;视觉诱发电位的波幅和潜伏期峰值可一定程度上反映视野损害的程度。展开更多
目的分析儿童抗接触蛋白相关蛋白-2(contactin-associated protein 2,Caspr2)抗体相关自身免疫性脑炎的临床特点、诊疗过程及预后情况,以期提高儿科医生对此病的认识。方法回顾性收集2019年6月至2022年6月山东大学附属儿童医院收治的抗C...目的分析儿童抗接触蛋白相关蛋白-2(contactin-associated protein 2,Caspr2)抗体相关自身免疫性脑炎的临床特点、诊疗过程及预后情况,以期提高儿科医生对此病的认识。方法回顾性收集2019年6月至2022年6月山东大学附属儿童医院收治的抗Caspr2抗体相关脑炎患儿4例,分析其临床资料的特征并进行随访。结果男女患儿各2例,年龄为1.3~7.0岁。4例均呈亚急性发病,首发症状表现为发热、惊厥发作4例,表现为自主神经功能障碍2例、头痛1例、精神行为异常1例;主要临床表现为意识障碍3例,言语障碍、运动障碍各2例,睡眠增多、反复头痛各1例。4例患儿头颅MRI检查和脑电图检查结果均存在异常。3例脑脊液Caspr2抗体阳性,4例血清Caspr2抗体阳性(其中1例复发时呈阳性)。3例行糖皮质激素联合免疫球蛋白治疗,1例行支持治疗,出院时病情均好转。出院后18~28个月进行随访,1例出现复发,4例改良Rankin评分0~2分。结论儿童抗Caspr2抗体相关脑炎临床表现不典型,常表现为意识障碍、发热、精神行为异常、睡眠障碍、癫痫、运动障碍、自主神经症状等。患儿对免疫治疗有较好的反应,早期诊断、早期治疗患儿预后良好。展开更多
文摘目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状病毒疫苗的新型冠状病毒感染诊断分型(轻型、中型、重型及危重型)的差别。阶段性总结新型冠状病毒感染住院患者的治疗情况及疗效分析;并促进各医院新型冠状病毒感染整体诊治水平的提高,指导康复及下一阶段可能出现高峰时的治疗。方法:回顾性收集并分析陕西省抗癫痫协会会员单位医院的其中10家医院的神经内科及神经外科在2022年12月13日~2023年1月31日期间收治的新型冠状病毒感染住院患者的临床资料,评价各型新型冠状病毒感染诊断分型中各治疗组疗效和接种疫苗对诊断分型的影响。结果:对363例患者临床资料进行统计学分析,在新型冠状病毒感染诊断分型为轻型的住院患者中,抗新型冠状病毒组与非抗新型冠状病毒组之间(P Objective: To compare the differences in the number of days of hospitalization and treatment outcomes in patients with the various diagnostic types of novel coronavirus infection with and without anti-novel coronavirus therapy, with and without hormone therapy, with and without antibiotic therapy, with and without traditional Chinese medicine, and vaccinated and unvaccinated against novel coronavirus;comparison of the diagnostic classification of novel coronavirus infections (mild, moderate, severe and critical) between those vaccinated and those not vaccinated against novel coronaviruses. We will summarize the treatment of hospitalized patients with novel coronavirus infections and analyze the therapeutic efficacy in a staged manner, and promote the improvement of the overall diagnosis and treatment of novel coronavirus infections in hospitals to guide the rehabilitation and the treatment of novel coronavirus infections in the next stage, when the peak may occur. Methods: Retrospective collection and analysis of clinical data of patients hospitalized with novel coronavirus infections admitted to the Department of Neurology and Department of Neurosurgery of 10 of the hospitals that are members of the Shaanxi Provincial Anti-Epilepsy Association during the period of December 13, 2022~January 31, 2023, to evaluate the efficacy of treatment groups in the diagnostic typing of novel coronavirus infections of each type and the effect of vaccination on the diagnostic typing. Results: The clinical data of 363 patients were statistically analyzed. Among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, there were statistically significant differences in hospital days between the anti-novel coronavirus group and the non-anti-novel coronavirus group (P < 0.001) and between the hormone group and the non-hormone group (P = 0.006). There was a statistically significant difference in hospital days between the antibiotic group and the non-antibiotic group among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, moderate and severe (P < 0.001, P = 0.005, P = 0.045), and between-group variability in treatment outcomes between the vaccine and non-vaccine groups among hospitalized patients whose diagnostic typology of novel coronavirus infection was medium (P = 0.024);the likelihood of a diagnosis of critical illness was higher in the non-vaccine than in the vaccine group, relative to the mild type (OR = 11.463, 95% CI 1.352~97.186, P = 0.025). Conclusions: The application of anti-novel coronavirus therapy, hormone therapy and antibiotic therapy may increase hospital days in hospitalized patients with a diagnostic classification of mild forms of novel coronavirus infection, and the application of antibiotic therapy in hospitalized patients with a diagnostic classification of moderate and severe forms of novel coronavirus infection;the vaccine group of hospitalized patients with a diagnostic classification of moderate forms of novel coronavirus infection was more likely to have a positive outcome of the treatment, relative to the control group. Vaccination may have a positive effect on preventing progression to critical type after COVID-19 infection.
文摘目的:探讨心血管危险因素对非动脉炎性前部缺血性视神经病变(NAION)的发生及视功能的影响。方法:选取2014-06/2018-06于我科就诊的单眼初发NAION患者(NAION组)和与其基本资料匹配的非NAION患者(对照组)各68例68眼,检测两组患者同型半胱氨酸(Hcy)、血脂、叶酸、维生素B12水平,并进行颈动脉多普勒超声检查,NAION组患者同时进行视功能检查。结果:与对照组相比,NAION组患者Hcy(24.8±13.9μmol/L vs 11.1±8.2μmol/L)、血浆中总胆固醇(4.5±1.0mmol/L vs 3.8±0.7mmol/L)、甘油三酯(2.0±0.9mmol/L vs 1.5±0.5mmol/L)、低密度脂蛋白(2.9±0.8mmol/L vs 2.3±0.5mmol/L)水平均升高(P<0.05),维生素B12水平明显下降(315.6±214.5pg/mL vs 467.9±198.2pg/mL,P<0.05),但两组患者颈内动脉阻力指数和内径无差异。NAION组患者患眼视野缺损值为16.6±7.5dB,Hcy、维生素B12、叶酸及血脂水平以及是否存在全身疾病均不是NAION视野损害的危险因素,而图形视觉诱发电位P100波幅和潜伏期峰值均与视野缺损值相关。结论:高同型半胱氨酸、高血脂和低维生素B12水平是NAION发生的危险因素,但与NAION的视野损害程度无关;视觉诱发电位的波幅和潜伏期峰值可一定程度上反映视野损害的程度。
文摘目的分析儿童抗接触蛋白相关蛋白-2(contactin-associated protein 2,Caspr2)抗体相关自身免疫性脑炎的临床特点、诊疗过程及预后情况,以期提高儿科医生对此病的认识。方法回顾性收集2019年6月至2022年6月山东大学附属儿童医院收治的抗Caspr2抗体相关脑炎患儿4例,分析其临床资料的特征并进行随访。结果男女患儿各2例,年龄为1.3~7.0岁。4例均呈亚急性发病,首发症状表现为发热、惊厥发作4例,表现为自主神经功能障碍2例、头痛1例、精神行为异常1例;主要临床表现为意识障碍3例,言语障碍、运动障碍各2例,睡眠增多、反复头痛各1例。4例患儿头颅MRI检查和脑电图检查结果均存在异常。3例脑脊液Caspr2抗体阳性,4例血清Caspr2抗体阳性(其中1例复发时呈阳性)。3例行糖皮质激素联合免疫球蛋白治疗,1例行支持治疗,出院时病情均好转。出院后18~28个月进行随访,1例出现复发,4例改良Rankin评分0~2分。结论儿童抗Caspr2抗体相关脑炎临床表现不典型,常表现为意识障碍、发热、精神行为异常、睡眠障碍、癫痫、运动障碍、自主神经症状等。患儿对免疫治疗有较好的反应,早期诊断、早期治疗患儿预后良好。
